2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Sunday, November 10, 2019

9:00AM-11:00AM: Abstract Number: 266

Measuring Advanced/Extended Practice Roles in Arthritis and Musculoskeletal Care in Canada: Stand up and Be Counted Too (2)!

Health Services Research Poster I – ACR/ARP

9:00AM-11:00AM: Abstract Number: 227

Metabolomic and Symptom Comparison in Women With/without Fibromyalgia: A Pilot Study

Fibromyalgia & Other Clinical Pain Syndromes Poster

9:00AM-11:00AM: Abstract Number: 128

Metabolomics Analysis Identifies Biomarkers for APS and Suggests a Potential New Pathway Related to APS Pathogenesis

Antiphospholipid Syndrome Poster

9:00AM-11:00AM: Abstract Number: 627

Metabolomics Screening in Axial Spondyloarthritis: Identifying Potential Biomarkers

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 362

Methods to Efficiently Recruit Minority Patients with Gout for Clinic-Based Registries

Metabolic & Crystal Arthropathies Poster I: Clinical

9:00AM-11:00AM: Abstract Number: 369

Methotrexate and Interstitial Lung Disease in Patients with Inflammatory Articular Disease: A Systematic Review

Miscellaneous Rheumatic & Inflammatory Disease Poster I: Fibroinflammatory & Granulomatous Disorders & Therapies

9:00AM-11:00AM: Abstract Number: 75

Microglia-Specific Transcriptional Signatures Correlate with Behavioral Deficits in ‘Neuropsychiatric Symptoms of Systemic Lupus Erythematosus’

SLE – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 119

Mitochondrial Transplantation Suppressed Muscle Inflammation and Improved the Mitochondrial Dysfunction in C Protein-induced Myositis Model

T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 729

Modelled Patient Level Skin Score Trajectory Predicts Risk of Death or Major Organ-Based Complications in Diffuse Cutaneous Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 545

Molecular Analysis of the Mode of Action of Upadacitinib in Rheumatoid Arthritis Patients: Whole Blood RNA Expression Data from the SELECT-NEXT Study

RA – Treatments Poster I: Novel Treatments

9:00AM-11:00AM: Abstract Number: 16

Monoclonal ACPA Promote Synovial Fibroblasts Migration Through a Peptidylarginine Deiminases (PAD) Dependent Pathway

Cytokines & Cell Trafficking Poster

9:00AM-11:00AM: Abstract Number: 727

Mortality and Morbidity in Scleroderma Renal Crisis: A Systematic Literature Review

Systemic Sclerosis & Related Disorders – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 672

Mouse SLE Studies Do Not Describe Human SLE

SLE – Clinical Poster I: Epidemiology & Pathogenesis

9:00AM-11:00AM: Abstract Number: 60

mTORC1-phosphorylated CXCR3+memory B Cells and Their Potential as a New Mode of Action of TNF Inhibitors in RA

RA – Etiology & Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 108

Mucosal Associated Invariant T Cells in Giant Cell Arteritis

T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].